The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Open accessAbstract
BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS: We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. RESULTS: A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Post hoc and prespecified subgroup analyses and meta-analyses of 5 major fibrate trialsdHelsinki Heart Study, Veterans Affairs HDL Intervention Trial, Bezafibrate Infarction Project, FIELD, and ACCORD-Lipiddhave shown a CV benefit in persons with moderate dyslipidemia (triglycerides >200 mg/dL and HDL-C <40 mg/dL, either isolated or together) but not in persons without dyslipidemia.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits in outcome studies appear limited to subgroups with high TG and low HDL-C, highlighting the complexity of translating TG reduction into ASCVD risk reduction [61, 74–77].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, traditional TG-lowering agents, such as fibrates and niacin, have demonstrated inconsistent CVD benefits in randomized trials, even when lipid changes were robust.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the recently concluded AIM-HIGH study did not report any further benefits with regard to cardiovascular events when niacin was added to a statin in patients with median triglyceride level of about 160 mg/dl in the mild hypertriglyceridemia range and average LDL cholesterol levels below 80 mg/dl (177).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“whether lowering these levels would also lower the incidence of cardiovascular events remains controversial.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“These neutral findings with pemafibrate are consistent with those from the contemporary Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) trial 2 of high-dose n-3 fatty acids, the previous Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (160)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (154) and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (155).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies, such as the Copenhagen City Heart Study involving 9330 individuals, indicate a progressive rise in myocardial infarction risk over a decade with increasing Lp(a) levels [13].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [30]
In the citing paper
“Combinations of statins with fibrates, niacin, or fish oil have thus far generally failed to demonstrate cardiovascular benefits beyond that achieved with statins alone.128–132”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [129]
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“In the Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial, treatment with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib increased HDL-C without any effect on LDL-C or ApoB, but did not reduce the risk of major CV events [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“Niacin also lowers LDL-C levels by 15–20%,49 but recent large randomized trials showed a significant excess of adverse effects and no significant CVD benefit when added to background statin treatment; therefore, niacin derivatives are no longer available for prescription in Europe.50,51”
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Twolarge randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Two large randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Modest regression of carotid atherosclerosis with niacin in most (but not all) imaging studies was not supported by clinical benefit in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Niacin did not reduce stroke over longterm follow-up in patients with CVD in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“With respect to primary endpoints of these studies, although the effectiveness of fenofibrate was not demonstrated, a meta-analysis in primary prevention using fibrates revealed that deaths from cerebrovascular and cardiovascular diseases, non-fatal myocardial infarction, and non-fatal stroke significantly decreased by 16%651).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [651]
In the citing paper
“Combination therapy using ethyl icosapentate (EPA) preparation or fibrate with statin is effective in suppressing ASCVD incidence. (Evidence level 2, recommendation level B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“In a sub-analysis of JELIS study696) which enrolled subjects with hypercholesterolemia, it was shown that EPA administration added-on to statins prevented coronary event incidence for patients in primary prevention whose TG and HDL-C levels were ≥ 151 mg/dL and < 40 mg/dL, respectively.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“Meta-analyses of studies with niacin (mostly without simultaneous administration of statins) indicate a decrease in cardiovascular events [92–94].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [92]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Flagged first, then by citations
Research works printed but not linked: 1
- Castelli WP, 1988, Can J Cardiol, 4, 5A
Cited by
Sorted by citations
Items 801–900 of 1,019
Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease
Teo, K. K., Goldstein, L. B., CHAITMAN, B. R., Grant, S., Weintraub, W. S., Anderson, D. C., Sila, C. A., Cruz‐Flores, S., Padley, R. J., Kostuk, W. J., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001529 · Cited by 39
The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia
Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.001 · Cited by 42
Influence of HDL particles on cell-cholesterol efflux under various pathological conditions
Asztalos, B. F., Horvath, K. V., Mehan, M. R., Yokota, Y., & Schaefer, E. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075648 · Cited by 39
Wacker, B. K., Dronadula, N., Bi, L., Stamatikos, A., & Dichek, D. A. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309565 · Cited by 39
Chieng, D., Pang, J., Ellis, K. L., Hillis, G. S., Watts, G. F., & Schultz, C. J. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.090 · Cited by 39
Shishikura, D., Kataoka, Y., Honda, S., Takata, K., Kim, S. W., Andrews, J., Psaltis, P. J., Sweeney, M., Kulikowski, E., Johansson, J., et al. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0298-8 · Cited by 39
Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome
Hackett, G. I. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.12.004 · Cited by 39
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Real-world utilization of bempedoic acid in an academic preventive cardiology practice
Warden, B. A., Cardiology, B.-A., Purnell, J. Q., Duell, P. B., & Fazio, S. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2021.11.013 · Cited by 39
Wang, Y., Fang, Y., Magliano, D. J., Charchar, F. J., Sobey, C. G., Drummond, G. R., & Golledge, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac124 · Cited by 39
Ebenezer, O., Comoglio, P., Wong, G. K.-S., & Tuszynski, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044019 · Cited by 39
Streja, E., Kovesdy, C. P., Streja, D. A., Moradi, H., Kalantar‐Zadeh, K., & Kashyap, M. L. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.033 · Cited by 39
Ewang-Emukowhate, M., & Wierzbicki, A. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413492906 · Cited by 39
Dullaart, R. P. F., Annema, W., Tio, R. A., & Tietge, U. J. F. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.02.026 · Cited by 41
Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis
Wacker, B. K., Dronadula, N., Zhang, J., & Dichek, D. A. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308258 · Cited by 39
Mørland, J. G., Magnus, P. M., Vollset, S. E., Leon, D. A., Selmer, R. M., & Tverdal, A. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad011 · Cited by 40
Is niacin ineffective? Or did AIM-HIGH miss its target?
Nicholls, S. J. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.11166 · Cited by 38
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 38
Toyama, K., Nishioka, T., Isshiki, A., Ando, T., Inoue, Y., Kirimura, M., Kamiyama, T., Sasaki, O., Ito, H., Maruyama, Y., et al. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6496-3 · Cited by 38
Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia
Wierzbicki, A. S., Hardman, T. C., & Viljoen, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679340 · Cited by 38
Sahebkar, A. (2014) · Vascular Medicine · doi:10.1177/1358863x13515766 · Cited by 41
Kim, D. S., Marsillach, J., Furlong, C. E., & Jarvik, G. P. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.147 · Cited by 43
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 38
Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium
Sposito, A. C., Faria‐Neto, J. R., de Carvalho, L. S. F., Lorenzatti, A. J., Cafferata, A., Elikir, G. D., Esteban, E., Villegas, E. C. M., Bodanese, L. C., Rodrigo Alonso, K., et al. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1252740 · Cited by 38
Managing Dyslipidemia in Type 2 Diabetes
Nelson, A. J., Rochelau, S. K., & Nicholls, S. J. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.004 · Cited by 38
Hippe, D. S., Phan, B. A. P., Sun, J., Isquith, D. A., O’Brien, K. D., Crouse, J. R., Anderson, T. J., Huston, J., Marcovina, S. M., Hatsukami, T. S., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310368 · Cited by 40
Gibson, C. M., Kernéis, M., Yee, M. K., Daaboul, Y., Korjian, S., Mehr, A. P., Tricoci, P., Alexander, J. H., Kastelein, J. J. P., Mehran, R., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.11.008 · Cited by 38
Becker, D. J., French, B., Morris, P. B., Silvent, E., & Gordon, R. Y. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.019 · Cited by 37
Hypertriglyceridemia: the importance of identifying patients at risk
Kushner, P. A., & Cobble, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1243005 · Cited by 47
Implications of reverse cholesterol transport: Recent studies
Levinson, S. S., & Wagner, S. G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.018 · Cited by 36
Wierzbicki, A. S., Clarke, R. E., Viljoen, A., & Mikhailidis, D. P. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328353adc1 · Cited by 39
Mantlo, N. B., & Escribano, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400574e · Cited by 37
Kühnast, S., Louwe, M. C., Heemskerk, M. M., Pieterman, E. J., van Klinken, J. B., van den Berg, S. A. A., Smit, J. W. A., Havekes, L. M., Rensen, P. C. N., van der Hoorn, J. W. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066467 · Cited by 37
Žák, A. (2015) · Medical Science Monitor · doi:10.12659/msm.893619 · Cited by 38
Kunutsor, S. K., Khan, H., Nyyssönen, K., & Laukkanen, J. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.069 · Cited by 37
Tran, J. N., Kao, T. C., Caglar, T., Stockl, K. M., Spertus, J. A., Lew, H. C., Solow, B. K., & Chan, P. S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.8.901 · Cited by 35
Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
Postmus, I., Warren, H. R., Trompet, S., Arsenault, B. J., Avery, C. L., Bis, J. C., Chasman, D. I., de Keyser, C. E., Deshmukh, H., Evans, D. S., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103966 · Cited by 38
Pleiotropic effects of niacin: Current possibilities for its clinical use
Zeman, M., Vecka, M., Perlík, F., Staňková, B., Hromádka, R., TVRZICKÁ, E., Širc, J., Hrib, J., & Žák, A. (2016) · Acta Pharmaceutica · doi:10.1515/acph-2016-0043 · Cited by 37
Efficient design of clinical trials and epidemiological research: is it possible?
Lauer, M. S., Gordon, D., Wei, G. S., & Pearson, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.60 · Cited by 37
He, X. M., Chen, X., Wang, L., Wang, W., Liang, Q., Yi, L., Wang, Y., & Gao, Q. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.09.024 · Cited by 37
Cholesteryl ester transfer protein: An enigmatic pharmacology – Antagonists and agonists
Yamashita, S., Ruscica, M., Macchi, C., Corsini, A., Matsuzawa, Y., & Sirtori, C. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.035 · Cited by 37
Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection
Bowman, E., & Funderburg, N. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00442-9 · Cited by 38
Arterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges
Csányi, G., & Singla, B. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040495 · Cited by 38
Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks
Shemesh, E., & Zafrir, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s188856 · Cited by 38
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
Castaño, D., Rattanasopa, C., Monteiro-Cardoso, V. F., Corlianò, M., Liu, Y., Zhong, A., Rusu, M., Liehn, E. A., & Singaraja, R. R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.013 · Cited by 37
Li, X., Ploner, A., Wang, Y., Zhan, Y., Pedersen, N. L., Magnusson, P. K. E., Jylhävä, J., & Hägg, S. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103318 · Cited by 37
Qian, Y., Pu, Y., Liu, L., Wang, D. Z., Zhao, X., Wang, C., Wang, Y., Liu, G., Pan, Y., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064395 · Cited by 37
Vazzana, N., Ganci, A., Cefalu, A. B., Lattanzio, S., Noto, D., Santoro, N., Saggini, R., Puccetti, L., Averna, M. R., & Davı̀, G. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000063 · Cited by 38
Familial hypercholesterolaemia: cholesterol efflux and coronary disease
Versmissen, J., Vongpromek, R., Yahya, R., van der Net, J. B., der Zee, L. V. V., Blommesteijn, J., Wattimena, D. J. L., Rietveld, T., Pullinger, C. R., Christoffersen, C., et al. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12643 · Cited by 37
Omega-3 fatty acids for cardiovascular event lowering
Kaur, G., Mason, R. P., Steg, P. G., & Bhatt, D. L. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae003 · Cited by 41
Lu, J. J.-Q., Hübner, K., Nanjee, M. N., Brinton, E. A., & Mazer, N. A. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003509 · Cited by 37
Williams, P. T., Zhao, X.-Q., Marcovina, S. M., Brown, B. G., & Krauss, R. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056782 · Cited by 36
Metrics of High-Density Lipoprotein Function and Hospital Mortality in Acute Heart Failure Patients
Potočnjak, I., Degoricija, V., Trbušić, M., Terešak, S. D., Radulović, B., Pregartner, G., Berghold, A., Tiran, B., Marsche, G., & Frank, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157507 · Cited by 37
Guirgis, F. W., Leeuwenburgh, C., Grijalva, V. R., Bowman, J., Kalynych, C. J., Moldawer, L. L., Moore, F. A., & Reddy, S. T. (2017) · Shock · doi:10.1097/shk.0000000000001030 · Cited by 37
The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD
Malhotra, R., Katz, R., Hoofnagle, A. N., Bostom, A. G., Rifkin, D. E., McBride, R., Probstfield, J. L., Block, G. A., & Ix, J. H. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05440517 · Cited by 37
Dai, W., Long, J., Cheng, Y., Chen, Y., & Zhao, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-25835-5 · Cited by 36
Teis, A., Cediel, G., Amigó, N., Julve, J., Aranyo, J. A., Andrés-Cordón, J. F., Puig-Jové, C., Castelblanco, E., Gual‐Capllonch, F., Ferrer‐Sistach, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82861-6 · Cited by 36
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
HDL cholesterol and clinical outcomes in diabetes mellitus
Ishibashi, T., Kaneko, H., Matsuoka, S., Suzuki, Y., Ueno, K., Ohno, R., Okada, A., Fujiu, K., Michihata, N., Jo, T., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad029 · Cited by 39
Role for Combination Therapy in Diabetic Dyslipidemia
Warraich, H. J., Wong, N. D., & Rana, J. S. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0589-5 · Cited by 36
Cardiovascular risk reduction with icosapent ethyl
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000678 · Cited by 33
Xie, S., Galimberti, F., Olmastroni, E., Carugo, S., Catapano, A. L., & Casula, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120420 · Cited by 40
Why Targeting HDL Should Work as a Therapeutic Tool, but Has Not
Sorci‐Thomas, M. G., & Thomas, M. J. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829d48a5 · Cited by 35
Mani, V., Woodward, M., Samber, D. D., Bucerius, J. A., Tawakol, A. A., Kallend, D. G., Rudd, J. H. F., Abt, M., & Fayad, Z. A. (2014) · International journal of cardiac imaging · doi:10.1007/s10554-014-0370-7 · Cited by 35
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 35
Mendelian Randomization and Estimation of Treatment Efficacy for Chronic Diseases
Schooling, C. M., Freeman, G., & Cowling, B. J. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws344 · Cited by 34
Novel concepts in HDL pharmacology
Remaley, A. T., Norata, G. D., & Catapano, A. L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu141 · Cited by 36
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 35
Translating Evidence of HDL and Plaque Regression
Bartolo, B. A. D., Psaltis, P. J., Bursill, C. A., & Nicholls, S. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.307026 · Cited by 38
Bashore, A. C., Liu, M., Key, C.-C. C., Boudyguina, E. Y., Wang, X., Carroll, C. M., Sawyer, J. K., Mullick, A. E., Lee, R. G., Macauley, S. L., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312382 · Cited by 36
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 35
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 37
Omega-3-fatty acids: Do they prevent cardiovascular disease?
Mason, R. P., Sherratt, S. C. R., & Eckel, R. H. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101681 · Cited by 39
Chen, H., Tsai, W., Chiu, Y., Hsu, S., Pai, M., Yang, J., & Peng, Y. (2015) · Medicine · doi:10.1097/md.0000000000000619 · Cited by 34
Hughes-Large, J. M., Pang, D., Robson, D. L., Chan, P., Toma, J., & Borradaile, N. M. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.090 · Cited by 35
Novel Therapies Focused on the High-Density Lipoprotein Particle
van Capelleveen, J. C., Brewer, H. B., Kastelein, J. J. P., & Hovingh, G. K. (2014) · Circulation Research · doi:10.1161/circresaha.114.301804 · Cited by 34
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 34
Sung, K., Ryu, S., Wild, S. H., & Byrne, C. D. (2015) · Heart · doi:10.1136/heartjnl-2014-306784 · Cited by 35
Pang, J., Chan, D. C., Hamilton, S. J., Tenneti, V. S., Watts, G. F., & Barrett, P. H. R. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302019 · Cited by 34
Stabilization of high-risk plaques
Takata, K., Imaizumi, S., Zhang, B., Miura, S., & Saku, K. (2016) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2015.10.03 · Cited by 40
Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
Barter, P. J., & Rye, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.021 · Cited by 35
Chen, Y., Rivera, J., Fitzgerald, M., Hausding, C., Ying, Y.-L., Wang, X., Todorova, K. O., Hayrabedyan, S., Barnea, E. R., & Peter, K. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0640 · Cited by 36
Goldberg, R. B., Bittner, V., Dunbar, R. L., Fleg, J. L., Grunberger, G., Guyton, J. R., Leiter, L. A., McBride, R., Robinson, J. G., Simmons, D. L., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.039 · Cited by 34
Cholesteryl ester transfer protein inhibitors: challenges and perspectives
Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2016.1189327 · Cited by 34
Targeting ApoC-III to Reduce Coronary Disease Risk
Khetarpal, S. A., Qamar, A., Millar, J. S., & Rader, D. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0609-y · Cited by 34
Ganda, A., Yvan‐Charvet, L., Zhang, Y., Lai, E. J., Regunathan-Shenk, R., Hussain, F. N., Avasare, R. S., Chakraborty, B., Febus, A. J., Vernocchi, L., et al. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.05.001 · Cited by 34
Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure
Greene, S. J., Mentz, R. J., Fiuzat, M., Butler, J., Solomon, S. D., Ambrosy, A. P., Mehta, C. R., Teerlink, J. R., Zannad, F. M., & O’Connor, C. M. (2018) · Circulation · doi:10.1161/circulationaha.118.034668 · Cited by 34
Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
Roberts, R. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.08.001 · Cited by 31
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Waldmann, E., & Parhofer, K. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.016 · Cited by 34
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
Gencer, B., & Mach, F. (2020) · Drugs · doi:10.1007/s40265-019-01243-5 · Cited by 35
Targeting HDL in tumor microenvironment: New hope for cancer therapy
Zhao, T., Zhu, N., Shi, Y., Wang, Y., Zhang, C., Deng, C., Liao, D., & Li, Q. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30412 · Cited by 36
Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Kalaycı, A., Gibson, C. M., Ridker, P. M., Wright, S. D., Kingwell, B. A., Korjian, S., Chi, G., Lee, J., Tricoci, P., Kazmi, S. H. A., et al. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01025-7 · Cited by 35
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Uceta, R. E., Guzman, E., & Rallidis, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713622 · Cited by 36
Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, T., Langsted, A., & Nordestgaard, B. G. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22013 · Cited by 37
Cardiovascular drugs that increase the risk of new-onset diabetes
Ong, K. L., Barter, P. J., & Waters, D. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2013.12.025 · Cited by 33
Lim, Y., Yoo, S., Lee, S. A., Chin, S. O., Heo, D., Moon, J. C., Moon, S., Boo, K., Kim, S. T., Seo, H. M., et al. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.2.208 · Cited by 35
Sun, R., Huang, C., Bao, J., Jiang, J., Zhang, B., Zhou, S., Cai, W., Wang, H., Wang, J., & Zhang, Y. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.714279 · Cited by 34
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases
Li, F., Wu, C., & Wang, G. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01072-3 · Cited by 37
Metadata
- Authors
- The AIM-HIGH Investigators
- Corresponding author
- The AIM-HIGH Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-15
- Volume
- 365
- Issue
- 24
- Pages
- 2255-2267
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2165605025
- Semantic Scholar
- d76ac03611110eeffa5c3ad8b47d06f372d84eb6
- Cited by
- 2,911
- References
- 19
- Citations by year
- 2026: 79 · 2025: 90 · 2024: 138 · 2023: 133 · 2022: 138 · 2021: 165 · 2020: 146 · 2019: 181 · 2018: 208 · 2017: 203 · 2016: 264 · 2015: 302 · 2014: 316 · 2013: 333 · 2012: 192
- FWCI
- 280.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- Sanofi
- Genentech
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- nicotinic acid, simvastatin, HDL cholesterol, low HDL cholesterol, residual cardiovascular risk, atherosclerotic cardiovascular disease, extended-release niacin, ezetimibe, LDL cholesterol, triglycerides, major adverse cardiovascular events, cardiovascular risk reduction, statin therapy, coronary artery disease, myocardial infarction, ischemic stroke, acute coronary syndrome, revascularization
- MeSH terms
- Aged, Hypolipidemic Agents, Cardiovascular Diseases, Brain Ischemia, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Muscular Diseases, Niacin, Triglycerides, Proportional Hazards Models, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Atherosclerosis, Kaplan-Meier Estimate, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
